BACKGROUND: Selective localization of dopamine D(4) receptors in the prefrontal cortex and preferential affinity of clozapine for the dopamine D(4) receptor over the D(2) receptor led to the hypothesis that the superior efficacy of clozapine may be mediated via blockade of the D(4) receptor. This hypothesis was tested by evaluating sonepiprazole, a selective D(4) dopamine antagonist, in schizophrenia patients. METHODS: We treated 467 hospitalized schizophrenia patients with scores of > or = 60 on the Positive and Negative Syndrome Scale (PANSS) withsonepiprazole, olanzapine, or placeboonce daily for 6 weeks. The primary efficacy end point was the mean change from baseline in the PANSS total score at 6 weeks. Secondary efficacy end points were the mean change from baseline in the PANSS factor scores, the Brief Psychiatric Rating Scale score, the Clinical Global Impressions Severity of Illness score, and the Calgary Depression Scale score. RESULTS: No statistically significant differences were observed between placebo and any sonepiprazole dose on the primary or any secondary end point after 6 weeks of treatment. Statistically significant differences, favoring olanzapine over placebo, were observed on all efficacy end points but the Calgary Depression Scale. CONCLUSIONS:Sonepiprazole was ineffective for the treatment of patients with schizophrenia.
RCT Entities:
BACKGROUND: Selective localization of dopamine D(4) receptors in the prefrontal cortex and preferential affinity of clozapine for the dopamine D(4) receptor over the D(2) receptor led to the hypothesis that the superior efficacy of clozapine may be mediated via blockade of the D(4) receptor. This hypothesis was tested by evaluating sonepiprazole, a selective D(4) dopamine antagonist, in schizophreniapatients. METHODS: We treated 467 hospitalized schizophreniapatients with scores of > or = 60 on the Positive and Negative Syndrome Scale (PANSS) with sonepiprazole, olanzapine, or placebo once daily for 6 weeks. The primary efficacy end point was the mean change from baseline in the PANSS total score at 6 weeks. Secondary efficacy end points were the mean change from baseline in the PANSS factor scores, the Brief Psychiatric Rating Scale score, the Clinical Global Impressions Severity of Illness score, and the Calgary Depression Scale score. RESULTS: No statistically significant differences were observed between placebo and any sonepiprazole dose on the primary or any secondary end point after 6 weeks of treatment. Statistically significant differences, favoring olanzapine over placebo, were observed on all efficacy end points but the Calgary Depression Scale. CONCLUSIONS:Sonepiprazole was ineffective for the treatment of patients with schizophrenia.
Authors: Enza Lacivita; Paola De Giorgio; Irene T Lee; Sean I Rodeheaver; Bryan A Weiss; Claudia Fracasso; Silvio Caccia; Francesco Berardi; Roberto Perrone; Ming-Rong Zhang; Jun Maeda; Makoto Higuchi; Tetsuya Suhara; John A Schetz; Marcello Leopoldo Journal: J Med Chem Date: 2010-10-28 Impact factor: 7.446
Authors: Taylor Moran-Gates; Christopher Grady; Young Shik Park; Ross J Baldessarini; Frank I Tarazi Journal: Eur Neuropsychopharmacol Date: 2006-12-18 Impact factor: 4.600
Authors: Richard H Andersson; April Johnston; Paul A Herman; Ursula H Winzer-Serhan; Irina Karavanova; Detlef Vullhorst; André Fisahn; Andres Buonanno Journal: Proc Natl Acad Sci U S A Date: 2012-07-20 Impact factor: 11.205
Authors: Frank I Tarazi; Taylor Moran-Gates; Erik H F Wong; Brian Henry; Mohammed Shahid Journal: Psychopharmacology (Berl) Date: 2008-02-24 Impact factor: 4.530